novarti report strong result sale ahead cs
consensu expect driver revenu out-performance includ
entresto gsk oncolog lucenti plu legaci hypertens portfolio
margin improv ahead consensu line cs
manag caution gener eros exjad afinitor plu
launch invest moder profit growth futur quarter
compani increas underli ebit growth guidanc top
prior rang novarti target mid-singl digit sale high singl
digit ebit growth
increas ep estim driven increas
expect entresto lutathera assum underli
sale growth underli ebit growth
cosentyx entresto novel growth driver off-set midterm gener
eros cosentyx continu grow highli competit market
entresto pick momentum see late-stag pipelin
crystallis strong launch potenti zolgensma sma gene therapi
mayzent ms posit trend drive posit margin mix
enabl novarti off-set patent expiri next year
potenti upsid depend length gilenya patent extens
howev larg reflect premium valuat view
catalyst risk zolgensma fda approv price
valuat novarti trade pe premium eu major
peer ex-azn novarti trade ev/npv vs eu peer
valuat metric
price-to-earnings rel local market
number share
price month
price rel chart measur perform
swiss market ind close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novarti provid healthcar solut compani
multi-national group compani special research
develop manufactur market rang healthcar
product led pharmaceut
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
scenario base pipelin success
higher peak sale cosentyx stronger sandoz
biopharma revenu gilenya patent life
extens
grey scenario base pipelin success lower
peak sale entresto lower cosentyx peak sale
lower sandoz growth
price rel chart measur perform swiss market
ind close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
figur novarti summari vs cs consensu
alcon discont op
share fd
chang forecast
increas revenu expect entresto lutathera follow strong growth
rel expect
includ aurobindo us oral solid dispos actual versu estim
previous gener continu oper ebit growth
report result includ impair develop
termin post-herpet neuralgia
fulli dilut share
fulli dilut share
fx impact sale
fx impact op incom
net financ adj alcon/ab
sale
line last year
mid- high singl digit cer
op incom
end
alreadi use
novarti premium/ discount eu
novarti premium/ discount global
 novarti
proof concept
major clinic mileston mayzent approv zolgensma data
major compani mileston complet alcon spin share buy-back end
continu strong grow dividend paid
dividend trend remain unchang post alcon spin
start deliv oper leverag innov medicin core margin
margin expect driven sale momentum launch
invest exist infrastructur progress novarti technic oper
novarti busi servic product abil hold core cost
cosentyx yoy strong us ex-u growth
china approv psoriasi march launch help continu
momentum outsid us
gain share psoriasi spondyloarthr
provid addit data rapid onset cosentyx
entresto yoy nbrx time high paragon-hf hfpef readout
entrestro best launch primari care drug sinc despit nation
oncolog driven full rang growth driver
promacta launch sever aplast anemia
mek taf growth adjuv melanoma combo trial
jakavi acut graft-versus-host diseas data expect end
lutathera expect lutathera blockbust new patient
sinc launch posit momentum eu reimburs uk itali
mayzent launch uniqu data spm expand believ novarti
differenti first dose monitor patient
zolgensma efficaci data sma type consist start data
support foundat use sma patient
prolong event free surviv earli rapid increas chop-intend score
zolgensma restor smn express motor neuron lack function
gene reach target tissu level similar non-sma subject
death report date respiratori failur unrel therapi pend
final assess contribut treatment eu jan month
old alreadi difficulti swallow patient die sepsi need wait
autopsi see zolgensma issu studi continu per protocol
sma surviv rate month patient fragil overal
zolgensma safe toler
patient treat zolgensma exclud due antibodi
us approv expect may deliveri infrastructur readi alreadi
establish centr us squar feet manufactur
space engag payer cover sma infant popul high
interest innov contract expect commerci live contract within
day line world class launch prepar
us launch readi top treatment centr familiar
anticip launch fda approv companion diagnost test
engag payer cover target popul us
asthma disease-modifi potenti readout track end
airway smooth muscl mass reduct asthma fevipipr
robust clinic program underway realiz full potenti
year global leadership experi gener gsk commerci digit
op incom cc driven good sale momentum product kick
drive gross margin cost off-set increas invest
free cash flow broadli line previou year
margin expans innov medicin
innov core margin expans track margin goal mid
exclud alcon sandoz us oral solid busi
rais core op high-singl digit follow strong
sandoz line prior year
new focus medicin adjust base
exclud us oral solid gener sale core oper
op incom impact
zolgensma sma
 zolgensma label expect neurolog complic time autopsi result
death pt
patient sadli die sepsi typic get neurolog complic read
across platform technolog appropri compani view regul
unconcern far kept inform everyth track chang
expect time approv label discuss fda regulatori
agenc go well provid updat see label fda
 valu base reimburs zolgensma per patient strive data
support analysi
depend valu use per qali icer recommend price
per patient
 sma payment come innov payment structur
vast major would prefer pay up-front budget alloc recognit
ifr would involv book major sale respect condit fulfil sale
may small rebat book recognis perform agreement
would depend payor deal novarti could use financ compani
 sma oral splice inhibitor file move forward
dose rang studi due inform futur plan
 sma data sma type patient penetr larg patient pool
proport type would elig much manufactur capac attribut
larg amount suitabl treatment larg patient popul depend
 sma on-going data look beyond type
dont want comment breadth label launch srtart studi
 increment margin zolgensma challeng patient alreadi drug like
quit high margin product high margin expect zolgensma product
significantli contribut cashflow
 zolgensma combo trial patient spinraza manufactur capac
convers move move patient spinraza zolgensma
enough capac deal think unpreced demand
 zolgensma advers event
dont see differ differ baselin characterist feel
good result
 zolgensma mechan could theoret caus death
aav therapi trigger enhanc trigger immun system need give steroid
appropri time aav given independ dsnb regul alreadi
said chang trial
 gilenya arbitr negoti mitsubishi royalti assum
novarti guidanc reflect current contractu agreement mt
comment arbitr outcom unlik chang guidanc
 pharma margin impress what done differ sustain
two key driver strong sale cosentyx entresto sale growth fall
bottom line strong cost disciplin also see oncolog also renew commit
product strong cog perform ambiti product programm brought
outstand leadership bring peopl outsid industri product
flow afinitor exjad patent expiri need
mind sustain
 buyback complet end year light
level share price one input time alcon spin good quit
optimist finish end year want maximis number share take
 gross margin innov medicin
product quit high gross margin product growth driver high margin
gleevec afinitor exjad gener impact neutralis effect expect gross
margin yr yr
 novartiss role cell therapi player pipelin focu expect novel antibodi
therapi critic long term abil gener new medicin state
cart cancer continu focu cell therapi addit bcma option recent
in-licens gen bispecif target cell cancer gen hematolog
eu china japan allianc crispr compani
 pipelin major launch best sale potenti bar one
excit whole rang zolgensma critic next gen tech beyond
lucenti first oral larg pop sever asthma provid transpar
next meet manag
file push year dme rvo
whole year term delay delay recruit rvo studi similar
quarter delay attribut logist
 manufactur challeng pharma margin antibodi product heavi
royalti burden rel lucenti
updat manufactur process track cog competit respect
biolog product
 ophthalmologist concern storag space extend limit
without sacrific visual acuiti retina specialist plu peopl feel
strongli interv fluid capac enough
 mayzent siponimod differenti could competitor enter space
novarti player specif spm other claim havent specif
studi doc interest drug proven data unlik mavenclad
 psoriasi risinkizumab label competit advantag cosentyx onset vs il-
psoriasi
market well serv risinkizumab dont think much gain
arrow studi mechan critic look forward ad
cosentyx demonstr psoriasi indic prefer drug
hard treat psoriasi differenti ankspond axspond
 updat expect time litig amgen aimovig co-promot
busi usual migrain patient confid posit us agreement
reli claus use look like us wont affect
 entresto us growth sustain underli volume demand
believ continu base paragon data
 ms quantifi destock gilenya underli demand mayzent vs
destock underli demand solid mayzent patient progress
posit regard patient
 jan reason target us rebat reform
novarti support remov rebat medicar part difficult judg time
impact know detail
 kisqali growth seem better
gather momentum drive expans indic broadest data
outsid us strong growth momentum increas penetr think
 tasigna sale perform soft
action plan return modest growth
 lutathera us sale ex-u split type patient net patient
vast major sale come us see good momentum
centr use treatment treat patient sale eu
patient lutathera clear data show benefit
situat chang compani initi regulatori procedur eu
novarti presum also us
work close fda find way forward collect addit data
legaci cv drug benefit gener suppli shortag unclear sustain
outstand china volum growth china entresto huge potenti cosentyx
approv entresto focu around volum even price pressur fine
focus drive launch aim doubl china busi year
 sandoz oral solid biz close come sale profit year
divest complet control aurobindo lead
process time court good forecast assumpt divest
complet provid pro-forma inform year
 sandoz biopharm sale weak trajectori uptick year
growth driven europ launch rixathond urelzi approv pegfilgastrin
soon hope give broad portfolio biosimilar
copaxon gener us continu launch state key pegfilgastrin
orelzai us replenish biosimilar portfolio us
basic number share
fulli dilut number share
compani mention price
